Search the Newsreel

HC Wainwright Issues Pessimistic Estimate for TRVI Earnings

What is HC Wainwright's Forecast for TRVI FY2030 Earnings?

1,525,314 Shares in Trevi Therapeutics, Inc. $TRVI Acquired by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. has acquired 1,525,314 shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) valued at approximately $28.4 million, representing about 1.07% of the company. Other institutional investors have also adjusted their holdings in TRVI, with institutional investors and hedge funds collectively owning 95.76% of …

Trevi Therapeutics (TRVI) Receives a New Rating from B. Riley Securities

Trevi Therapeutics, Inc. Stock 12‑Month Price Target Raised to $29.17, Implies 58% Upside

Analysts have increased the average 12-month price target for Trevi Therapeutics, Inc. (TRVI) stock from $27.33 to $29.17, with estimates ranging from $23 to $40 per share. This updated target suggests a potential upside of approximately 58% from the Aug. 6 closing price. The …

Trevi Therapeutics (NASDAQ:TRVI) Announces Earnings Results, Hits Estimates

Trevi Therapeutics (NASDAQ:TRVI) announced its quarterly earnings, reporting a loss of $0.11 per share, which met analyst expectations. The company confirmed its clinical programs are on track, with Phase II and III chronic cough trials advancing, and it maintains a strong liquidity position with …

Trevi Therapeutics (TRVI) Starts Key Cough Trials, Is It Still 29% Below Fair Value?

Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Trevi Therapeutics announced its second quarter 2026 financial results, highlighting the initiation of its Phase 3 OCEAN-1 trial for IPF-related chronic cough and the Phase 2b LAKE trial for refractory chronic cough. The company reported $318.9 million in cash and marketable securities, extending its …

Cantor Fitzgerald Forecasts Strong Price Appreciation for Trevi Therapeutics (NASDAQ:TRVI) Stock

Trevi Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary

Trevi Therapeutics, Inc. has released its earnings summary for the quarter that concluded on June 30. The article, provided by Refinitiv and featured on TradingView, offers an overview of the company's financial performance. Readers can access the full report and further analysis on the …

Trevi Therapeutics Inc (TRVI) (Q2 2026) Earnings Call Highlights: Advancing Phase 3 Pipeline ...

Trevi Therapeutics Inc (TRVI) is making significant progress with its Phase 3 clinical pipeline, including trials for IPF-related chronic cough and refractory chronic cough. The company boasts a strong cash position of $319 million, extending its runway into 2030 and funding key programs through …

Earnings call transcript: Trevi Therapeutics posts small Q2 2026 EPS miss

Trevi Therapeutics, Inc. 2Q 2026: Net loss $17.8M, EPS $(0.11) — 10-Q Summary

Trevi Therapeutics, Inc. reported a net loss of $17.8M for the second quarter of 2026, an increase from $12.3M in the prior year, with diluted EPS at $(0.11). The company highlighted significant clinical advancements, including positive Phase 2b and 2a results, initiation of Phase …

Trevi Therapeutics stock edges lower despite upbeat earnings call

Trevi Therapeutics faces earnings test as Haduvio trials advance

Trevi Therapeutics is preparing to report its second-quarter financial results, with analysts expecting a wider loss per share as the company advances its Haduvio trials for chronic cough. Investor focus will be on pipeline updates and cash runway, especially after a key competitor exited …

FMR LLC discloses 8.8% Trevi Therapeutics (TRVI) ownership in amended 13G

FMR LLC and Abigail P. Johnson have disclosed an 8.8% passive ownership stake in Trevi Therapeutics (TRVI), according to an amended 13G filing. This represents 12,562,839.08 shares of Trevi's common stock, over which they have sole dispositive power. The filing also clarifies that no …

Trevi Therapeutics (TRVI) Earnings Date and Reports 2026 $TRVI

Trevi Therapeutics (NASDAQ: TRVI) funds late-stage cough trials with $318.9M

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Average Rating of "Buy" from Analysts

Analysts have issued a consensus "Buy" rating for Trevi Therapeutics, Inc. (NASDAQ:TRVI) based on reports from twelve brokerages, with an average 12-month price target of $24.91. Institutional investors hold a significant 95.76% of the company's stock, with several major funds increasing their positions. Despite …

Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

Trevi Therapeutics announced it will release its second quarter 2026 financial results on August 6, 2026. The company will also provide a corporate update during a webcast and conference call on the same day. Investors and interested parties can access the call via phone …

Trevi Therapeutics Q2 Results: Earnings call set for Aug 6

Trevi Therapeutics, Inc. will host a conference call on August 6, 2026, to discuss its second-quarter 2026 financial results and provide a corporate update. The company is developing Haduvio (oral nalbuphine extended-release) for chronic cough associated with IPF, non-IPF ILD, and RCC, conditions for …

Trevi Therapeutics sets Aug. 6 update on chronic-cough therapy

Trevi Therapeutics (TRVI) announced it will host a conference call and live audio webcast on August 6, 2026, at 4:30 p.m. ET to discuss its second-quarter 2026 financial results and provide a corporate update. The company is a clinical-stage biopharmaceutical firm developing Haduvio for …

Trevi Therapeutics (TRVI) to Post Earnings on Thursday

Trevi Therapeutics (NASDAQ:TRVI) is scheduled to release its Q2 2026 earnings after market close on Thursday, August 6th, with analysts anticipating a loss of $0.11 per share. The company's stock currently holds an average "Buy" rating from analysts, alongside a consensus price target of …

Trevi Therapeutics Inc (TRVI) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Trevi Therapeutics Inc (TRVI), detailing its support, resistance levels, and key indicators. It presents a summary of various technical indicators like MACD, RSI, and moving averages, offering insights into potential buy, sell, or neutral signals. The analysis …

Trevi's CEO and CFO join August biotech events in two states

Trevi Therapeutics (Nasdaq: TRVI) announced that its senior management, including CEO Jennifer Good and CFO David Hastings, will participate in two biotech conferences in August 2026. The company will attend Oppenheimer's Biotech in the Berkshires on August 4 and Stifel's 2026 Biotech Summer Summit …

Trevi Therapeutics to Participate in Upcoming August Conferences

Trevi Therapeutics, Inc. announced that its senior management will participate in two upcoming conferences in August: Oppenheimer's Biotech in the Berkshires on August 4, 2026, and Stifel's 2026 Biotech Summer Summit from August 10-12, 2026. The company is developing Haduvio™ (oral nalbuphine ER) for …

Trevi Therapeutics, Inc. Revenue Breakdown – NASDAQ:TRVI

Trevi Therapeutics, Inc. $TRVI Shares Sold by Orbimed Advisors LLC

Orbimed Advisors LLC significantly reduced its stake in Trevi Therapeutics (NASDAQ:TRVI) by 23.1% in the first quarter, selling 736,300 shares but still retaining 2.45 million shares valued at approximately $29.3 million. Despite missing analyst EPS estimates for its latest quarter, analysts maintain a "Buy" …

Octagon Capital Advisors LP Reduces Stock Holdings in Trevi Therapeutics, Inc. $TRVI

Octagon Capital Advisors LP significantly reduced its stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 47.2% in the first quarter, selling 1.33 million shares but still retaining 1.485 million shares valued at $17.7 million. Despite this reduction, institutional ownership in Trevi Therapeutics remains high at …

Trevi Therapeutics Inc (TRVI) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on the dividend and stock split history for Trevi Therapeutics Inc (TRVI). It states that Trevi Therapeutics has not distributed any dividends over the past 5 years. The page displays current stock information such as its market capitalization and P/E …

Trevi Therapeutics Inc (TRVI) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Trevi Therapeutics Inc (TRVI), noting its current stock price, market cap, and a 2.06% increase. Key valuation metrics such as P/E, P/B, and P/CF ratios are listed as not disclosed by the company yet. The page offers …

Trevi Therapeutics Inc (TRVI) Institutional Confidence

This article provides details on the institutional confidence in Trevi Therapeutics Inc (TRVI), listing major shareholders and their recent activity. It shows the number of shares held by top institutions and the percentage change in their holdings. The stock TRVI closed at $17.535 with …

Trevi Therapeutics Inc (TRVI) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Trevi Therapeutics Inc (TRVI), highlighting that 12 analysts currently rate the stock as a "Buy" with a target price of $27.545, representing a 60.33% upside. It details the company's recent EPS performance and future expectations, alongside a …